Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-12

  Gustavsson, Carin ^a   Agardh, Carl David ^a   Zetterqvist, Anna V ^a   Nilsson, Jan ^a   Agardh, Elisabet ^a   Gomez, Maria F ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; STREPTOZOCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION REGULATION; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOFLUORESCENCE MICROSCOPY; INFLAMMATION; LIPID DIET; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETINA BLOOD VESSEL; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE; ANIMAL; C57BL MOUSE; DISEASE MODEL; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; MOUSE MUTANT; UPREGULATION;

MUS;

ANIMALS; DIABETIC RETINOPATHY; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RETINAL VESSELS; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77958573925     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012699     Document Type: Article

References (57)

1. Kern TS (2007) Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy. Exp Diabetes Res 2007. 95103 p.
2. Hartge MM, Unger T, Kintscher U (2007) The endothelium and vascular inflammation in diabetes. Diab Vasc Dis Res 4: 84-88.
3. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, et al. (2006) Diabetic Retinopathy: Seeing Beyond Glucose-Induced Microvascular Disease. Diabetes 55: 2401-2411.
4. Khan ZA, Chakrabarti S (2007) Cellular signaling and potential new treatment targets in diabetic retinopathy. Exp Diabetes Res 2007. 31867 p.
5. Khalfaoui T, Lizard G, Ouertani-Meddeb A (2008) Adhesion molecules (ICAM-1 and VCAM-1) and diabetic retinopathy in type 2 diabetes. J Mol Histol, 2008/01/01 ed. pp 243-249.
6. Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94: 3171-3182.
7. van Buul JD, Kanters E, Hordijk PL (2007) Endothelial signaling by Ig-like cell adhesion molecules. Arterioscler Thromb Vasc Biol 27: 1870-1876.
8. Gustavsson C, Agardh E, Bengtsson B, Agardh CD (2008) TNF-alpha is an independent serum marker for proliferative retinopathy in type 1 diabetic patients. J Diabetes Complications 22: 309-316.
9. Nguyen TT, Alibrahim E, Islam FMA, Klein R, Klein BEK, et al. (2009) Inflammatory, Hemostatic, and Other Novel Biomarkers for Diabetic Retinopathy: The Multi-Ethnic Study of Atherosclerosis. Diabetes Care 32: 1704-1709.
10. Klein BE, Knudtson MD, Tsai MY, Klein R (2009) The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol 127: 1175-1182.
11. Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868-874.
12. Videm V, Albrigtsen M (2008) Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol 67: 523-531.
13. Spijkerman AM, Gall MA, Tarnow L, Twisk JW, Lauritzen E, et al. (2007) Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in Type 2 diabetes. Diabet Med 24: 969-976.
14. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer CD, Ebeling P, et al. (2006) Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in Type 1 diabetic patients. J Diabetes Complications 20: 188-195.
15. Barile GR, Chang SS, Park LS, Reppucci VS, Schiff WM, et al. (1999) Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res 19: 219-227.
16. Limb GA, Hickman-Casey J, Hollifield RD, Chignell AH (1999) Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 40: 2453-2457.
17. Hatchell DL, Wilson CA, Saloupis P (1994) Neutrophils plug capillaries in acute experimental retinal ischemia. Microvasc Res 47: 344-354.
18. Adamiec-Mroczek J, Oficjalska-Mlynczak J (2008) Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes--role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 246: 1665-1670.
19. Matsumoto K, Sera Y, Ueki Y, Inukai G, Niiro E, et al. (2002) Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy. Diabet Med 19: 822-826.
20. Nowak M, Wielkoszynski T, Marek B, Kos-Kudla B, Swietochowska E, et al. (2008) Blood serum levels of vascular cell adhesion molecule (sVCAM-1), intercellular adhesion molecule (sICAM-1) and endothelial leucocyte adhesion molecule-1 (ELAM-1) in diabetic retinopathy. Clin Exp Med 8: 159-164.
21. Galkina E, Ley K (2009) Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 27: 165-197.
22. Leiter LA (2005) The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering? Diabetes Res Clin Pract 68 Suppl 2: S3-14.
23. (1997) Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes 46: 1829-1839.
24. Lyons TJ, Jenkins AJ, Zheng D, Lackland DT, McGee D, et al. (2004) Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45: 910-918.
25. Dodson PM (2009) Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality? Eye 23: 997-1003.
26. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, et al. (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370: 1687-1697.
27. The ASGaAESG Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med: NEJMoa1001288.
28. Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM (1985) Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest 76: 1501-1513.
29. Adamis AP, Berman AJ (2008) Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol 30: 65-84.
30. Bertazza L, Mocellin S (2008) Tumor necrosis factor (TNF) biology and cell death. Front Biosci 13: 2736-2743.
31. Chadwick W, Magnus T, Martin B, Keselman A, Mattson MP, et al. (2008) Targeting TNF-alpha receptors for neurotherapeutics. Trends Neurosci 31: 504-511.
32. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, et al. (2008) Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 19: 231-244.
33. Wu KK, Huan Y (2007) Diabetic atherosclerosis mouse models. Atherosclerosis 191: 241-249.
34. Hsueh W, Abel ED, Breslow JL, Maeda N, Davis RC, et al. (2007) Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 100: 1415-1427.
35. Nilsson-Öhman J, Fredrikson GN, Nilsson-Berglund LM, Gustavsson C, Bengtsson E, et al. (2009) Tumor Necrosis Factor-a Does Not Mediate Diabetes-Induced Vascular Inflammation in Mice. Arterioscler Thromb Vasc Biol.
36. Engelhardt B (2006) Molecular mechanisms involved in T cell migration across the blood-brain barrier. J Neural Transm 113: 477-485.
37. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. The Lancet 376: 124-136.
38. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, et al. (2009) Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 4: e8158.
39. Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, et al. (2008) Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales' disease. Retina 28: 817-824.
40. Patel JI, Saleh GM, Hykin PG, Gregor ZJ, Cree IA (2008) Concentration of haemodynamic and inflammatory related cytokines in diabetic retinopathy. Eye (Lond) 22: 223-228.
41. de Gooyer TE, Stevenson KA, Humphries P, Simpson DA, Gardiner TA, et al. (2006) Retinopathy is reduced during experimental diabetes in a mouse model of outer retinal degeneration. Invest Ophthalmol Vis Sci 47: 5561-5568.
42. Mohr S, Xi X, Tang J, Kern TS (2002) Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51: 1172-1179.
43. Gustavsson C, Agardh CD, Hagert P, Agardh E (2008) Inflammatory markers in nondiabetic and diabetic rat retinas exposed to ischemia followed by reperfusion. Retina 28: 645-652.
44. Johnsen-Soriano S, Sancho-Tello M, Arnal E, Navea A, Cervera E, et al. IL-2 and IFN-gamma in the retina of diabetic rats. Graefe's Archive for Clinical and Experimental Ophthalmology 248: 985-990.
45. Collins T, Cybulsky MI (2001) NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 107: 255-264.
46. Barile GR, Pachydaki SI, Tari SR, Lee SE, Donmoyer CM, et al. (2005) The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 46: 2916-2924.
47. Zhang H, Park Y, Wu J, Chen X, Lee S, et al. (2009) Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 116: 219-230.
48. Ferrante AW, Jr. (2007) Obesity-induced inflammation: a metabolic dialogue in the language of inflammation. J Intern Med 262: 408-414.
49. Azcutia Vn, Abu-Taha M, Romacho T, Vázquez-Bella M, Matesanz N, et al. Inflammation Determines the Pro -Adhesive Properties of High Extracellular D - Glucose in Human Endothelial Cells In Vitro and Rat Microvessels In Vitro. PLoS ONE 5: e10091.
50. Eugster HP, Muller M, Karrer U, Car BD, Schnyder B, et al. (1996) Multiple immune abnormalities in tumor necrosis factor and lymphotoxin-alpha doubledeficient mice. Int Immunol 8: 23-36.
51. Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, et al. (2009) TNFalpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis 15: 1418-1428.
52. Chomczynski P (1993) A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 15: 532-534, 536-537.
53. Agardh E, Gustavsson C, Hagert P, Nilsson M, Agardh CD (2006) Modifying a standard method allows simultaneous extraction of RNA and protein, enabling detection of enzymes in the rat retina with low expressions and protein levels. Metabolism 55: 168-174.
54. Navaratna D, McGuire PG, Menicucci G, Das A (2007) Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 56: 2380-2387.
55. Agardh CD, Gustavsson C, Hagert P, Nilsson M, Agardh E (2006) Expression of antioxidant enzymes in rat retinal ischemia followed by reperfusion. Metabolism 55: 892-898.
56. Ameli S, Hultgardh-Nilsson A, Cercek B, Shah PK, Forrester JS, et al. (1994) Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 90: 1935-1941.
57. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502